We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.


BioFocus DPI Signs two Drug Discovery Collaborations with Ono

Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: Less than a minute

Galapagos NV as announced that its BioFocus DPI service division has signed two new collaborations with Ono Pharmaceutical Company Ltd. These collaborations build on the successful relationship between Ono and DPI, which began in 2004.

Under the first collaboration, BioFocus DPI will use selected compounds from its SoftFocus and other synthetic small molecule collections to perform high throughput screening for Ono's drug discovery program.

In the second collaboration, BioFocus DPI will apply its medicinal and computational chemistry and ADME profiling expertise in multiple medicinal chemistry projects for Ono.

"We are pleased with the new contracts with Ono that build on the longstanding relationship between Ono and DPI.  The new contracts show the benefit of building a global drug discovery service business. We combine expertise from our acquired companies Discovery Partners International, BioFocus as well as Inpharmatica, realizing the synergy in bringing these activities together," added Onno van de Stolpe, Chief Executive Officer of Galapagos.

"We are dedicated to creating innovative medicines," said Dr. Daikichi Fukushima, Managing Director, Ono. "Accordingly, we are enthusiastic about extending the relationship with BioFocus DPI, a leading company in drug discovery, so that we can continue creating novel drug candidates."